InvestorsHub Logo
Followers 16
Posts 2682
Boards Moderated 0
Alias Born 09/16/2004

Re: None

Thursday, 06/15/2006 10:53:05 PM

Thursday, June 15, 2006 10:53:05 PM

Post# of 38
C.E Unterberg initates TRCA with an Underperform and a $2-3 tgt saying they expect continued clarity into the progress of Increlex's launch, they remain cautious on its future prospects. They say their cautiousness stems from Tercica's inferior safety profile when compared to that of its main competitor, Insmed's IPLEX. The firm notes Increlex had a 68% incidence of adverse events in its pivotal clinical trial compared to 48% for IPLEX

http://www.briefing.com/Investor/Public/MarketAnalysis/Calendars/UpgradesDowngra desAlphaSort.htm


Peace!

C-Starz

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TRCA News